#GNIGroupInc

Gyre Therapeutics plans to fully acquire Cullgen in Q2 2026 and will propose issuance of common shares upon conversion of Series B convertible preferred stock at the shareholders meeting.

The consolidated revenue forecast for the fiscal year ending December 2026 is 27.158 billion yen, expected to increase approximately 1.2% compared to the previous fiscal year, while profit items remain undisclosed due to significant uncertainties.

Our consolidated subsidiary Gyre Therapeutics submitted a New Drug Application (NDA) in China on March 22, 2026, for F351, a therapeutic agent for liver fibrosis derived from chronic hepatitis B.

For the fiscal year ending December 2025, consolidated revenue was JPY 26,840 million (up 13.7% YoY), operating loss was JPY 3,471 million, and net loss attributable to owners of parent was JPY 4,244 million. Total assets increased to JPY 83,791 million and total equity rose to JPY 51,842 million.

Revised consolidated earnings forecast for the fiscal year ending December 2025 with revenue at 284.1 billion yen (down 6.6% from previous forecast) and net income attributable to owners of parent at a loss of 3.42 billion yen. Expected exclusion of listing gain from Cullgen’s postponed IPO and recording of impairment loss of 468 million yen.